Follow

BioStock: Nya lovande data i Scandion Oncologys cancerstudie

05 August 2020 - 11:08

I slutet av förra veckan rapporterade Scandion Oncology fas II-data från den första kohorten av kemoterapiresistenta kolorektala cancerpatienter som behandlats med bolagets läkemedelskandidat SCO-101 i kombination med den vanliga kemoterapin FOLFIRI. Resultaten ser uppmuntrande ut inför den fortsatta utvecklingen. 

Läs hela artikeln på biostock.se:

https://www.biostock.se/2020/08/nya-lovande-data-i-scandion-oncologys-cancerstudie/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se/

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date